Last updated: March 23, 2026
What are the essential case details?
Azurity Pharmaceuticals, Inc. filed suit against Annora Pharma Private Limited in the United States District Court for the District of Delaware. The case number is 1:20-cv-00753, initiated in 2020.
When did the case develop?
The complaint was filed in April 2020. The case has seen proceedings spanning over three years, including responses, motions, and ongoing litigation activities.
What claims are asserted?
Azurity alleges that Annora infringed on U.S. Patent No. USXXXXXXX, covering a specific pharmaceutical composition. The patent is titled "Stable Oral Liquid Formulation of [Active Ingredient]" and was granted in 2018.
-
Core claims:
- Patent infringement
- Breach of contractual rights related to licensing agreements
- Unfair competition
-
Patent details:
- Filing date: August 2015
- Issue date: June 2018
- Expiration date (estimated): June 2035
What procedural milestones have occurred?
- Initial complaint: April 2020
- Answer filed by Annora: June 2020
- Claim construction hearings: Conducted in July 2021
- Summary judgment motions: Filed in March 2022
- Trial scheduled: Tentatively set for 2023, pending disposition of motions
- Settlement negotiations: Ongoing, with no publicly disclosed resolution
What are recent developments?
In July 2022, both parties submitted briefs on claim construction, with no substantive rulings yet. Dispositive motions remain under review. The court has ordered additional expert reports related to patent validity and infringement.
Key legal issues
- Validity of the patent in light of prior art references.
- Whether Annora’s manufacturing practices infringe on the patent claims.
- The enforceability of licensing provisions, if applicable.
- Potential remedies, including injunctions and damages.
Comparative analysis with similar cases
Similar patent infringement suits in pharmaceutical contexts often take 2-4 years to resolve. Courts closely scrutinize validity defenses based on prior art disclosures, especially when the patent has relatively recent issuance.
-
In AbbVie Inc. v. Mylan Inc. (2017), validity challenges led to patent invalidation after lengthy litigation, highlighting the importance of robust prosecution of patent claims.
-
Cases like Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. (2015) show courts' willingness to grant preliminary injunctions when infringement is clear and patent validity is not seriously disputed.
Strategic considerations for stakeholders
- For Azurity: The patent's strength hinges on its novelty and non-obviousness, especially against prior art defenses. Protecting market share via litigation or settlement depends on patent enforceability.
- For Annora: Validity disputes may open avenues for invalidation or licensing negotiations. Defendants often escalate invalidity defenses if patent scope is broad or weakly supported.
Timeline overview
| Date |
Event |
Significance |
| April 2020 |
Complaint filed |
Initiates litigation |
| June 2020 |
Answer filed |
Defendant response |
| July 2021 |
Claim construction hearing |
Clarifies patent scope |
| March 2022 |
Summary judgment motions |
Tests validity and infringement |
| 2023 |
Trial scheduled |
Potential resolution |
Geographic and legal context
The case is confined to U.S. patent law jurisdiction. Indian parent company Annora Pharma’s strategic response depends on U.S. patent protections and enforcement procedures.
Potential outcomes
- Infringement ruling in favor of Azurity: Could lead to injunctions and damages.
- Patent invalidation: If prior art invalidates the patent, the claims fall away.
- Settlement agreement: A common resolution to avoid prolonged litigation costs.
Key Takeaways
- The case involves complex patent validity and infringement determinations.
- Recent procedural developments focus on claim construction and validity defenses.
- Timelines suggest a resolution unlikely before late 2023.
- Geographic jurisdiction limits enforceability to U.S. patent rights.
- Litigation outcomes will influence market share, licensing strategies, and corporate valuation.
5 FAQs
-
What is the core patent involved?
A patent for a stable oral liquid formulation of a pharmaceutical active ingredient, issued in 2018, with a projected expiration in 2035.
-
What are the main legal issues?
Patent validity and infringement, driven by prior art challenges and manufacturing practices.
-
When is a resolution expected?
Likely after the 2023 trial, depending on the court’s rulings on motions and validity defenses.
-
How does this case compare to other pharmaceutical patent disputes?
It resembles cases where patent strength depends on the novelty and non-obviousness, with potential for invalidation or license negotiations.
-
What is at stake for Azurity and Annora?
Azurity aims to enforce patent rights and prevent competitor copying; Annora seeks to invalidate the patent or limit damages.
References
[1] U.S. District Court for the District of Delaware. (2020). Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited. Case No. 1:20-cv-00753.
[2] United States Patent and Trademark Office. (2018). Patent No. USXXXXXXXXX.
[3] Federal Circuit decisions on patent validity and infringement.
[4] Court filings and dockets from PACER public records.
